Analyst Ratings for Revance Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Revance Therapeutics (NASDAQ:RVNC) within the last quarter, with 7 bullish, 1 somewhat bullish, and 3 indifferent. In the last 3 months, 11 analysts have offered 12-month price targets for Revance Therapeutics, with an average price target of $33.82, a decrease of 13.01% from the previous average price target of $38.88.
October 11, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts' ratings for Revance Therapeutics are mostly bullish, but the average 12-month price target has decreased by 13.01% from the previous target.
The majority of analysts are bullish on Revance Therapeutics, indicating a positive outlook for the company. However, the decrease in the average 12-month price target suggests that analysts may be adjusting their expectations downwards, which could potentially impact the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100